Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB

FASEB J. 2001 Jul;15(9):1622-4. doi: 10.1096/fj.00-0716fje.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Celecoxib
  • Cyclooxygenase 2
  • Dinoprostone / metabolism
  • Disease Models, Animal
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Interleukin-1 / metabolism
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • Male
  • NF-kappa B / metabolism*
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Pyrazoles
  • Rats
  • Rats, Sprague-Dawley
  • Sulfonamides / administration & dosage
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*
  • Transcription, Genetic / drug effects
  • Tumor Necrosis Factor-alpha / metabolism
  • Zymosan

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Interleukin-1
  • Isoenzymes
  • NF-kappa B
  • Pyrazoles
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • Zymosan
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib
  • Dinoprostone